Clinical Trial

Pulmonary Vascular Dysfunction as a Cause of Persistent Exertional Dyspnea After Coronavirus Disease (COVID-19)

Study acronym: PulmVasC
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
To identify pulmonary vascular disease in post/long-COVID-19 patients as a cause of dyspnea/exercise limitation and to differentiate it from other causes of dyspnea
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-05-13; most recent amendment 2025-09-03.
Status change: Recruiting → Active, Not Recruiting 2025-09-03
Trial Details
NCT Number NCT05374577
Lead Sponsor University of Giessen
Conditions COVID-19
Enrollment 200 participants
Start Date 2022-04-15
Primary Completion 2025-03-31 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-09-04